Lower systemic levels of ApoA-I have been correlated with greater disease activity and higher disability scores in MS patients [145], reinforcing the notion that ApoA-I status could serve as a valuable indicator of disease severity and treatment response. This evidence concerns the gene APOA1 and myeloid sarcoma.